Overuse of antibiotics in meat production causes human antimicrobial resistance, diseases and gut-related disorders, leading to 1.2m life-threatening hospital infections and 19,000 deaths from MRSA-bacteria each year. The best solution is sustainable antibiotic-free food production, improved food safety and nutrition value, wider use of probiotics and increased functional foods production.
Companies like Bon Appétit, Tyson Foods, Smithfield, McDonald's, etc. are voluntarily banning antibiotics treated food products. To meet this trend and EU regulations, new cost-effective technologies for processing delicate substances and active ingredients are needed in EU.
Vegan and other plant-based diets have created a strong market need for advanced food technologies - e.g. microencapsulation that follows their requirements. So far most capsules for food supplements, etc. are not vegan and thus do not address that growing market.
Uniq Bioresearch has developed and patented ACTIWHEY® microencapsulation technology that addresses these challenges and market trends and provides market-leading nutritional efficiency; extended shelf-life, increased food safety and countless new opportunities for food, feed and nutraceuticals manufacturers.
ACTICAPS project achieved to 1) reduce the microencapsulation costs; 2) extend the encapsulation opportunities in food, feed and nutraceuticals market, 3) achieve market-leading fill-coating ratio; 4) improve controlled release and other key advantages; 5) create a scale-up package, incl. process planning strategy, production manuals and licensing concept; 6) validate the innovation in different market segments for fast market uptake.
